Display options
Cite
Yang YA, Yu J. Current perspectives on FOXA1 regulation of androgen receptor signaling and prostate cancer. Genes Dis. 2015;2(2):144-151doi: 10.1016/j.gendis.2015.01.003.
Yang, Y. A., & Yu, J. (2015). Current perspectives on FOXA1 regulation of androgen receptor signaling and prostate cancer. Genes & diseases, 2(2), 144-151. https://doi.org/10.1016/j.gendis.2015.01.003
Yang, Yeqing Angela, and Yu, Jindan. "Current perspectives on FOXA1 regulation of androgen receptor signaling and prostate cancer." Genes & diseases vol. 2,2 (2015): 144-151. doi: https://doi.org/10.1016/j.gendis.2015.01.003
Yang YA, Yu J. Current perspectives on FOXA1 regulation of androgen receptor signaling and prostate cancer. Genes Dis. 2015 Jun;2(2):144-151. doi: 10.1016/j.gendis.2015.01.003. PMID: 26114156; PMCID: PMC4477823.
Copy Download .nbib Format: NLM
Share it on

Genes Dis. 2015 Jun;2(2):144-151. doi: 10.1016/j.gendis.2015.01.003.

Current perspectives on FOXA1 regulation of androgen receptor signaling and prostate cancer.

Genes & diseases

Yeqing Angela Yang, Jindan Yu

Affiliations

  1. Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
  2. Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA ; Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.

PMID: 26114156 PMCID: PMC4477823 DOI: 10.1016/j.gendis.2015.01.003

Abstract

FOXA1 (also known as hepatocyte nuclear factor 3α, or HNF-3α) is a protein of the FKHD family transcription factors. FOXA1 has been termed as a pioneer transcription factor due to its unique ability of chromatin remodeling in which the chromatin can be decompacted to allow genomic access by nuclear hormone receptors, including androgen receptor (AR) and estrogen receptor (ER). In this review, we discuss our current understanding of FOXA1 regulation of prostatic and non-prostatic AR-chromatin targeting. We present an updated model wherein FOXA1:AR equilibrium in the nuclei defines prostatic AR binding profile, which is perturbed in prostate cancer with FOXA1 and/or AR de-regulation. Finally, we discuss recent efforts in exploring new horizons of AR-independent functions of FOXA1 in prostate cancer and interesting directions to pursue in future studies.

Keywords: Androgen receptor; Chromatin accessibility; EMT; FOXA1; Pioneering factor; Prostate cancer

References

  1. Cell. 2009 Jul 23;138(2):245-56 - PubMed
  2. Dev Biol. 2002 Oct 1;250(1):1-23 - PubMed
  3. Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10152-7 - PubMed
  4. Endocr Relat Cancer. 2009 Jun;16(2):381-9 - PubMed
  5. Nat Rev Genet. 2009 Apr;10(4):233-40 - PubMed
  6. Cell. 2008 Mar 21;132(6):958-70 - PubMed
  7. Cancer Res. 2002 Sep 15;62(18):5273-9 - PubMed
  8. Prostate. 2005 Mar 1;62(4):339-52 - PubMed
  9. Mol Pharmacol. 2010 Oct;78(4):714-22 - PubMed
  10. Mol Cell Biol. 1989 Apr;9(4):1415-25 - PubMed
  11. Genome Res. 2011 Apr;21(4):555-65 - PubMed
  12. Trends Genet. 2011 Jun;27(6):224-32 - PubMed
  13. Development. 1993 May;118(1):47-59 - PubMed
  14. Nat Commun. 2014 May 30;5:3972 - PubMed
  15. Cell. 1989 May 19;57(4):645-58 - PubMed
  16. Clin Cancer Res. 2009 Jun 1;15(11):3680-9 - PubMed
  17. Cell Cycle. 2013 Jan 15;12(2):379-80 - PubMed
  18. Cancer Res. 2013 Mar 1;73(5):1570-80 - PubMed
  19. Mol Cell. 2007 Aug 3;27(3):380-92 - PubMed
  20. Front Oncol. 2013 Feb 14;3:20 - PubMed
  21. Cell. 2005 Jul 15;122(1):33-43 - PubMed
  22. Cancer Res. 2010 Mar 1;70(5):2115-25 - PubMed
  23. Int J Oncol. 2010 Feb;36(2):321-30 - PubMed
  24. Nature. 2005 Jun 16;435(7044):944-7 - PubMed
  25. Am J Physiol Lung Cell Mol Physiol. 2005 Nov;289(5):L750-9 - PubMed
  26. EMBO J. 2011 Sep 13;30(19):3962-76 - PubMed
  27. Nucleic Acids Res. 2015 Jan;43(2):e7 - PubMed
  28. Mol Cell. 2002 Feb;9(2):279-89 - PubMed
  29. Gene Expr Patterns. 2004 Dec;5(2):193-208 - PubMed
  30. Nature. 2012 Jul 12;487(7406):239-43 - PubMed
  31. Nature. 1993 Jul 29;364(6436):412-20 - PubMed
  32. Oncogene. 2005 Feb 24;24(9):1580-8 - PubMed
  33. Development. 1993 Dec;119(4):1301-15 - PubMed
  34. Genome Res. 2011 Jan;21(1):47-55 - PubMed
  35. Cancer Res. 2006 Aug 1;66(15):7783-92 - PubMed
  36. Mol Cancer Res. 2009 Apr;7(4):511-22 - PubMed
  37. Cell. 2014 Sep 25;159(1):176-87 - PubMed
  38. J Biol Chem. 2005 Apr 8;280(14):13809-16 - PubMed
  39. J Biol Chem. 1998 Aug 7;273(32):20213-22 - PubMed
  40. Dev Biol. 2003 Jan 15;253(2):165-74 - PubMed
  41. Nat Genet. 2012 May 20;44(6):685-9 - PubMed
  42. Histopathology. 2011 Apr;58(5):766-72 - PubMed
  43. Am J Pathol. 2012 Feb;180(2):848-61 - PubMed
  44. Nucl Recept Signal. 2008 Feb 01;6:e001 - PubMed
  45. Front Cell Neurosci. 2014 Sep 09;8:275 - PubMed
  46. Mol Endocrinol. 2003 Aug;17(8):1484-507 - PubMed
  47. Genes Dev. 2008 Dec 15;22(24):3435-48 - PubMed
  48. BMC Genomics. 2013 Oct 04;14:680 - PubMed
  49. Nature. 2011 May 15;474(7351):390-4 - PubMed
  50. Cancer Res. 2013 Jun 15;73(12):3725-36 - PubMed
  51. Development. 2010 Jun;137(12):2045-54 - PubMed
  52. EMBO J. 1998 Jan 2;17(1):244-54 - PubMed
  53. Nat Med. 2014 Mar;20(3):272-82 - PubMed
  54. Genes Dev. 1999 Feb 15;13(4):495-504 - PubMed
  55. Development. 2005 Aug;132(15):3431-43 - PubMed
  56. Development. 1993 Nov;119(3):567-78 - PubMed
  57. EMBO J. 2011 Sep 20;30(19):3885-94 - PubMed
  58. Genome Res. 2009 Mar;19(3):372-80 - PubMed
  59. Lab Invest. 2014 Jul;94(7):726-39 - PubMed

Publication Types

Grant support